To our knowledge, the case presented here is the first report of atezolizumab and bevacizumab effectively used in the second-line setting following progression on single-agent anti-PD-1 therapy, and specifically suggests that VEGF inhibition can overcome resistance to checkpoint inhibition in HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.